| Autor: |
Salih, Boga, Abdullah Emre, Yildirim, Enver, Ucbilek, Ali Riza, Koksal, Sevil Tokdemir, Sisman, Ibrahim, Durak, Ilker, Sen, Beril, Dogu, Erdinc, Serin, Ayse Bolat, Ucbilek, Makbule Ozge, Yildirim, Sukru Mehmet, Erturk, Huseyin, Alkim, Canan, Alkim |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
European Journal of Gastroenterology & Hepatology. 34:1261-1268 |
| ISSN: |
0954-691X |
| Popis: |
Sarcopenia is one of the most significant contributors to morbidity in patients with chronic liver disease. Serum myokines are potential biomarkers for detecting early sarcopenia. We aimed to investigate the relationship between serum myokines and cirrhosis-related mortality in the early stages of the disease.In total, 262 patients and 50 healthy controls were enrolled in this study, which was designed as a multicenter cross-sectional study. At the beginning of the study, sarcopenia was defined by computed tomography scans using the third lumbar vertebra skeletal muscle index. Serum myostatin, irisin, and follistatin levels, nutritional status of the patients, and muscle strength as measured by the handgrip test were recorded. Cirrhosis-related mortality and overall survival were evaluated in the fourth year of the study as the second checkpoint of cross-sectional analysis.A total of 145 (55.3%) patients were diagnosed with sarcopenia. Multivariate analysis revealed that low BMI, high levels of myostatin, and decreased irisin levels were independent predictors of sarcopenia. While serum irisin level was the most predictive parameter in terms of 4th-year cirrhosis-related mortality in the CHILD A group, serum myostatin levels were found more indicative in the CHILD BC group regardless of sarcopenia status ( Plt; 0.001).Serum myostatin levels predict sarcopenia in all stages of cirrhosis. Serum irisin levels can also be used as a potential biomarker to predict both treatable sarcopenia and cirrhosis-related mortality in CHILD A patients. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
